Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China
Launched by H. LUNDBECK A/S · Mar 15, 2012
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with idiopathic PD.
- • Patients with a Modified Hoehn and Yahr stage \<3.
- Exclusion Criteria:
- • Patients with a clinically significant or unstable medical or surgical condition that would preclude his/her safe and complete study participation.
- • Patients with a clinically significant or unstable vascular disease.
- • Patients with a clinically significant psychiatric illness, including a major depression, which compromises their ability to provide consent or participate fully in the study.
- • Patients with a Mini Mental State Examination (MMSE) score ≤24.
- • Patients with a diagnosis of melanoma or a history of melanoma, or a suspicious lesion.
- • Other inclusion and exclusion criteria may apply.
About H. Lundbeck A/S
H. Lundbeck A/S is a global pharmaceutical company dedicated to improving the quality of life for patients with brain disorders. Founded in 1915 and headquartered in Denmark, Lundbeck specializes in research, development, manufacturing, and marketing of innovative treatments for conditions such as depression, schizophrenia, and Alzheimer's disease. With a strong commitment to neuroscience, Lundbeck invests significantly in clinical trials to advance the understanding and treatment of psychiatric and neurological disorders, aiming to deliver effective solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Beijing, , China
Chengdu, , China
Guangzhou, , China
Guangzhou, , China
Hangzhou, , China
Shanghai, , China
Shanghai, , China
Shanghai, , China
Suzhou, , China
Wuhan, , China
Xi'an, , China
Guangzhou, , China
Wuhan, , China
Xi'an, , China
Patients applied
Trial Officials
Email contact via H. Lundbeck A/S
Principal Investigator
LundbeckClinicalTrials@lundbeck.com
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials